Vaccine stabilising company moves closer to licensing activity
This article was originally published in Scrip
Executive Summary
Stabilitech, a UK company developing a stabilisation technology that enables vaccines and biopharmaceuticals to be stored at a wide range of temperatures, has initiated discussions on licensing terms for potential deals with partners that have been conducting feasibility studies, CEO Dr Barbara Domayne-Hayman told Scrip.